FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1–Selected Patients With NSCLC
Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.05.004
Full Text
Open PDFAbstract
Available in full text
Date
November 1, 2018
Authors
Publisher
Elsevier BV